StockData
Phio Pharmaceuticals Corp. logo

Phio Pharmaceuticals Corp. (PHIO) stock

PHIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30
$0.72+0.00 (+0.43%)

Close on Nov 18, 2026Market cap $8.37MP/E –Yield –

Phio Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Phio Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was -$12.21M. For fiscal 2025 it was -$7.99M. The highest annual figure on record is -$5.08M in fiscal 2012.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$7.99M–
FY2024Dec 31, 2024-$7.11M–
FY2023Dec 31, 2023-$10.75M–
FY2022Dec 31, 2022-$12.25M–
FY2021Dec 31, 2021-$11.91M–
FY2020Dec 31, 2020-$8.82M–
FY2019Dec 31, 2019-$8.72M–
FY2018Dec 31, 2018-$7.53M–
FY2017Dec 31, 2017-$9.72M–
FY2016Dec 31, 2016-$7.76M–
FY2015Dec 31, 2015-$7.37M–
FY2014Dec 31, 2014-$7.85M–
FY2013Dec 31, 2013-$6.39M–
FY2012Dec 31, 2012-$5.08M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$4.04M–
Q1 FY2026Mar 31, 2026-$4.00M–
Q4 FY2025Dec 31, 2025-$2.08M–
Q3 FY2025Sep 30, 2025-$2.09M–
Q2 FY2025Jun 30, 2025-$2.54M–
Q1 FY2025Mar 31, 2025-$1.28M–
Q4 FY2024Dec 31, 2024-$1.37M–
Q3 FY2024Sep 30, 2024-$1.95M–
Q2 FY2024Jun 30, 2024-$1.78M–
Q1 FY2024Mar 31, 2024-$2.01M–
Q4 FY2023Dec 31, 2023-$2.37M–
Q3 FY2023Sep 30, 2023-$2.90M–
Q2 FY2023Jun 30, 2023-$2.78M–
Q1 FY2023Mar 31, 2023-$2.71M–
Q4 FY2022Dec 31, 2022-$2.71M–
Q3 FY2022Sep 30, 2022-$3.53M–
Q2 FY2022Jun 30, 2022-$2.44M–
Q1 FY2022Mar 31, 2022-$3.57M–
Q4 FY2021Dec 31, 2021-$2.47M–
Q3 FY2021Sep 30, 2021-$2.90M–
Q2 FY2021Jun 30, 2021-$3.27M–
Q1 FY2021Mar 31, 2021-$3.27M–
Q4 FY2020Dec 31, 2020-$2.62M–
Q3 FY2020Sep 30, 2020-$1.98M–
Q2 FY2020Jun 30, 2020-$2.03M–
Q1 FY2020Mar 31, 2020-$2.19M–
Q4 FY2019Dec 31, 2019-$2.54M–
Q3 FY2019Sep 30, 2019-$2.05M–
Q2 FY2019Jun 30, 2019-$1.95M–
Q1 FY2019Mar 31, 2019-$2.18M–
Q4 FY2018Dec 31, 2018-$1.75M–
Q3 FY2018Sep 30, 2018-$2.01M–
Q2 FY2018Jun 30, 2018-$1.86M–
Q1 FY2018Mar 31, 2018-$1.91M–
Q4 FY2017Dec 31, 2017-$2.20M–
Q3 FY2017Sep 30, 2017-$2.21M–
Q2 FY2017Jun 30, 2017-$2.50M–
Q1 FY2017Mar 31, 2017-$2.80M–
Q4 FY2016Dec 31, 2016-$1.37M–

More Phio Pharmaceuticals figures

See a number that looks wrong?